Skip to main content
. 2019 May 23;63(6):e02673-18. doi: 10.1128/AAC.02673-18

FIG 2.

FIG 2

Probabilities of target attainment of liposomal amphotericin B (L-AMB) monotherapy for A. fumigatus isolates with different CLSI AMB MICs and different L-AMB doses in simulated neutropenic and nonneutropenic patients (top). Cumulated fractional response (CFR) adjusted based on adverse events (adjCFR) in simulated neutropenic and nonneutropenic patients (bottom).